Biomarkers of immune dysfunction in HIV

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 498-503

  Nixon, Daniel E ^a   Landay, Alan L ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarker; C reactive protein; D dimer; HIV; immune activation; immune senescence; interleukin 6

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL MARKER; D DIMER; INTERLEUKIN 6;

BACTERIAL TRANSLOCATION; BLOOD CLOTTING DISORDER; CYTOKINE PRODUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; INFLAMMATION; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SENESCENCE;

ANTIGENS, CD; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL AGING; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6;

EID: 78049314539     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833ed6f4     Document Type: Review

References (59)

1. Lifson AR, Belloso WH, Carey C, et al. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008; 9:177-185.
2. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
3. Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infectious Dis 2010; 201:285-292.
4. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: elationship to in vivo coagula tion and immune activation. Blood 2010; 115:161-167.
5. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
6. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
7. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
8. Rodger AJ, Fox Z, Lundgren JD. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-983.
9. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207: 524-529.
10. Boulware D, Huppler HullsiekK, Puronen C, et al. Higher levels of D-dimer, C-reactive protein (CRP), hyaluronic acid and IL-6 before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death among ART-naïve patients with a good virologic response to initial ART. In: Abstract #335, 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA; 2010.
11. Ledwaba L, Maja P, the Phidisa Predictors of Mortality Substudy Team. Pre-ART plasma levels of inflammatory and coagulation markers are strong predictors of death after commencing ART in a South African cohort with advanced HIV infection. In:5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa; 2009.
12. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune DeficSyndr 2008; 48:142-148.
13. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-1805
14. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110:1911-1928.
15. Bermudez LE, Wu M, Petrofsky M, Young LS. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun 1992; 60:4245-4252.
16. Nordoy I, Muller F, Nordal KP, et al. The role of the tumour necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2000; 181:51-57.
17. Franceschi C, Capri M, Monti D, et al. Inflammaging and antiinflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128:92-105.
18. Cipriano C, Caruso C, Lio D, et al. The -308G/A polymorphism of TNF-alpha influences immunological parameters in old subjects affected by infectious diseases. Int J Immunogenet 2005; 32:13-18.
19. Jong E, Louw S, Meijers JC, et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009; 23:1001-1007.
20. Pontrelli G, Martino AM, Tchidjou HK, et al. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS 2010; 24:1145-1151.
21. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
22. Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456-464.
23. Ciccone EJ, Read SW, Mannon PJ, et al. Cycling of gut mucosal CD4 + T cells decreases after prolonged antiretroviral therapy and is associated with plasma LPS levels. Mucosal Immunol 2010; 3:172-181.
24. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
25. Anselmi A, Vendrame D, Rampon O, et al. Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to antiretroviral therapy. Clin Exp Immunol 2007; 150:442-450.
26. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
27. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. JID 1999; 179:859-970.
28. Cao W, Jamieson BD, Hultin LE, et al. Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses 2009; 25:183-191.
29. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10.
30. Bourgeois C, Hao Z, Rajewsky K, et al. Ablation of thymic export causes accelerated decay of naïve CD4 T cells in the periphery because of activation by environmental antigen. Proc Natl Acad Sci USA 2008; 105:8691-8696.
31. Voss S, Welte S, Fotin-Mleczek M, et al. A CD14 domain with lipopolysac-charide-binding and -neutralizing activity. Chembiochem 2006; 7:275-286.
32. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host-cell interactions. J Endotoxin Res 2005; 11:225-229.
33. Papasavvas E, Pistilli M, Reynolds G, et al. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 2009; 23:369-375.
34. Marchetti G, Cozzi-Lepri A, Bellistri GM, et al. Role of microbial translocation and immune hyperactivation in disease progression of HIV+ patients with preserved CD4 count in the absense of ART Abstract #333. In: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA; 2010.
35. Sandler N, Wand H, Nixon D, et al. Plasma levels of soluble CD14 predict mortality in HIV infection Abstract #335. In: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA; 2010.
36. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coliO:113 endotoxin. J Infect Dis 1999; 179:1278-1282.
37. Baker JV, INSIGHT Study Group. Levels of inflammatory and coagulation markers after starting HAART Abstract #280, 47th Infectious Diseases Society of America Meeting, Philadelphia, PA; 2009.
38. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939
39. Hamlyn E, Boyd K, Porter K, et al. IL-6 and D-dimer in primary HIV infection: effect of short course ART and treatment discontinuation. In: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA; 2010.
40. Olmo MM, Alonso-Villaverde C, Penaranda M, et al. Impact of HAART interruption on plasma inflammatory markers associated with CVD. Final 36 month results from a randomized study. In: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa; 2009.
41. Van Vonderen MG, Hassink EA, van Agtmael MA, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199:1186-1194.
42. Chen L, Jarujaron S, Wu X, et al. HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages. Biochem Pharmacol 2009; 78:70-77.
43. Vatier C, Leroyer S, Quette J, et al. Human subcutaneous adipose tissue is highly sensitive to lipopolysaccharide- and nelfinavir-induced inflammation while visceral fat is resistant. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada; 2009.
44. Zhou H, Jarujaron S, Gurley EC, et al. HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis 2007; 195:e134-e143.
45. Wu X, Sun L, Zha W, et al. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010; 138:197-209
46. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707-715.
47. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty- related phenotypeand progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 2009; 50:299-306.
48. Pawelec G, Derhovanessian E, Larbi A, et al. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009; 19:47-56.
49. Pita-Lopez ML, Gayoso I, DelaRosaO, et al. Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors. Immun Ageing 2009; 6:11.
50. Naeger DM, Martin JN, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5.
51. Van de Berg PJ, Griffiths SJ, Yong SL, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol 2010; 184:3417-3423.
52. Czesnikiewicz-GuzikM, Lee WW, Cui D, et al. Tcell subset-specific susceptibility to aging. Clin Immunol 2008; 127:107-118.
53. Focosi D, Bestagno M, Burrone O, Petrini M. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 2010; 87:107-116.
54. Petrovas C, Chaon B, Ambrozak D, et al. Differential association of pro- grammed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol Methods 2009; 183:1120-1132.
55. Merino J, Martinez-Gonzalez MA, Rubio M, et al. Progressive decrease of CD8high+ CD28+ CD57- cells with ageing. Clin Exp Immunol 1998; 112:48-51.
56. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+T cells. Blood 2003; 101:2711-2720.
57. Desai SR, Usuga X, Martinson J, et al. Immune senescence, activation and abnormal T cell homeostasis despite effective HAART, a hallmark of early aging in HIV. Presented at 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal; 2009.
58. Cao W, Jamieson BD, Hultin LE, et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009;50:137-147.
59. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.